Bondlido Topical System Approved for Postherpetic Neuralgia

The Food and Drug Administration (FDA) has approved Bondlido^® (lidocaine topical system 10%) for the relief of pain associated with postherpetic neuralgia in adults.

Bondlido is a drug-in-adhesive topical delivery system containing 200mg of lidocaine, an amide local anesthetic. Each topical system is 10cm × 14cm × 0.066cm and is applied to the skin to cover the most painful area. 

According to manufacturer MEDRx, the Bondlido lidocaine patch incorporates a proprietary technology that allows for firm adhesion to the skin, with reduced irritation. Study results showed that in adults wearing Bondlido covering the thoracic dermatomes T8-T10, 98 of the 100 topical systems applied exhibited 75% or greater surface area adhesion at all timepoints evaluated throughout the 12-hour wear period.

The safety and efficacy of Bondlido were supported by clinical trial data from a different lidocaine topical system. Pharmacokinetics data from a study involving 20 healthy adults undergoing exercise after Bondlido application showed a modest 20% reduction in systemic exposure over the 12 hour period. No statistically significant changes in absorption or pharmacokinetics were observed when an occlusive dressing was applied over the Bondlido patch and worn for 12 hours. 

Bondlido should be applied to intact skin; a maximum of 2 topical systems may be applied only once for up to 12 hours within a 24-hour period. The efficacy of a lidocaine topical system does not necessarily correlate with dosage strength due to differences in bioavailability. The amount of lidocaine absorbed is directly related to both duration of application and the surface area over which it is applied. In a single-dose, crossover study conducted in 32 healthy volunteers, Bondlido demonstrated equivalent systemic exposure and peak concentration of lidocaine to a lidocaine topical system 5%. 

Bondlido is supplied in a carton containing 28 topical systems. The product is expected to be available in the first half of 2026. 

This article originally appeared on MPR